Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 2/20 | 0.36 |
| ▸ | HMGCR | P04035 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | EYA2 | O00167 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | MLYCD | O95822 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 3/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26309085 | 0.83 | — | — | |
| SCHEMBL10197374 | 0.82 | TDP1 (0.35) | ADRA1AHMGCRCHRM1TBXA2RTDP1 | |
| SCHEMBL783010 | 0.81 | TDP1 (0.41) | ADRA1AHMGCRCHRM1TBXA2RTDP1 | |
| SCHEMBL24709971 | 0.79 | TDP1 (0.36) | ADRA1ATDP1EYA2APPACE | |
| SCHEMBL22291050 | 0.77 | TDP1 (0.35) | ADRA1AHMGCRCHRM1TBXA2RTDP1 | |
| SCHEMBL22734368 | 0.75 | — | — | |
| SCHEMBL3871128 | 0.75 | FFAR3 (0.36) | ADRA1AHMGCRCHRM1TBXA2RTDP1 | |
| SCHEMBL11800317 | 0.74 | ADRA1A (0.43) | ADRA1AHMGCRCHRM1TBXA2RTDP1 | |
| SCHEMBL1547956 | 0.74 | ADRA1A (0.43) | ADRA1AHMGCRCHRM1TBXA2RTDP1 | |
| SCHEMBL14199728 | 0.73 | TDP1 (0.35) | ADRA1AHMGCRCHRM1TBXA2RTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | ADRA1A 2516/4885HMGCR 1520/4885CHRM1 4314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.